Date: 13 Nov 2018 | More Details Here
Tessa Therapeutics was honored to host Chinese Premier Li Keqiang on his first official visit to Singapore as Premier, where we discussed our commitment to clinical research and the need for international cooperation to develop new ways to fight cancer.
2018年11月12日，中国李克强总理上任以来首次访问新加坡。11月13日，Tessa (特沙公司) 非常荣幸地接待了李总理的到访，详细介绍了公司的研发理念和进展。李总理鼓励新中两国企业开展研发合作，减轻癌症患者的病痛和家庭负担。更多详情请参考: http://paper.people.com.cn/rmrb/html/2018-11/14/nw.D110000renmrb_20181114_3-02.htm
Tessa Therapeutics Media Contacts
Will Carnwath, Ben Fry
+65 6426 8188
About Tessa Therapeutics
Tessa Therapeutics is a clinical stage biopharmaceutical company with the scientific vision of revolutionizing the treatment of cancer by redirecting the body’s potent anti-viral immune response to recognize and kill cancer cells. Tessa’s virus-specific T cell (VST) platform has shown compelling results in the treatment of solid tumors, and the Company is building a portfolio of therapies addressing a wide range of tumors by combining the qualities of its T cell platform with complementary technologies. Tessa’s lead Phase III trial for nasopharyngeal carcinoma (NPC) is the world’s largest Phase III T cell immunotherapy trial for any cancer indication. The Company is also conducting a Phase I trial targeting cervical cancer and oropharyngeal cancer which is expected to move into Phase II in 2019. In addition, Tessa is developing a broad pipeline of pre-clinical programs targeting major cancers such as liver and lung cancer. The Company has built up robust operational and supply chain capabilities to successfully deliver T cell therapy treatments to a large patient pool across five countries. The combination of technologies from its academic, clinical, and commercial research partners have enabled Tessa to create a fully-integrated approach to the treatment of cancer with immunotherapy. For more information on Tessa, please visit www.tessatherapeutics.com.